Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01085903 · ClinicalTrials.gov registry record · Phase 2
Identifying and Treating Arousal Related Deficits in Neglect and Dysphagia
A Phase 2 study, sponsored by University of Arkansas.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT01085903: Completed Phase 2 study, sponsored by University of Arkansas.
NCT01085903 is a Phase 2 study that has completed, run by University of Arkansas. The registered enrollment target is 28 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (79% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01085903, a Phase 2 study, has completed, sponsored by University of Arkansas.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
The purpose of this study is to examine how stroke can alter arousal, alertness, neglect and dysphagia, and whether a medication, modafinil, can improve arousal.
Primary Outcome
This is an electrophysiological measure of arousal - a percent change in the P50 evoked response potential amplitudes with a 250 ms inter stimulus interval. The difference score is calculated as CPS - baseline and as modafinil - placebo (stroke subjects only).
Interventions
- DRUG Placebo
- DRUG Modafinil
- BEHAVIORAL Baseline
- BEHAVIORAL CPS
- BEHAVIORAL Post CPS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2010-03 |
| Est. Completion | 2015-08 |
| Phase | Phase 2 |
What the finished NCT01085903 record still lists
NCT01085903 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (79% lower).
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT01085903 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01085903 about?
NCT01085903 is a clinical study titled "Identifying and Treating Arousal Related Deficits in Neglect and Dysphagia". The purpose of this study is to examine how stroke can alter arousal, alertness, neglect and dysphagia, and whether a medication, modafinil, can improve arousal.
What is the current status of trial NCT01085903?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2010-03. Estimated completion is 2015-08.
What interventions are being tested in trial NCT01085903?
The interventions under investigation include: Placebo (DRUG), Modafinil (DRUG), Baseline (BEHAVIORAL), CPS (BEHAVIORAL), Post CPS (BEHAVIORAL).
Who is sponsoring clinical trial NCT01085903?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01085903's enrollment target sits among peer trials
28 1677th of 2000 higher than 304 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia